Health Discovery has discovered a new set of genetic biomarkers related to prostate cancer (PCA). This newly discovered gene set is expected to lead to considerable improvement in the diagnosis and treatment of clinically significant PCA.These biomarkers have been shown to accurately separate high-grade PCA from less malignant grades, with a high degree of accuracy. This ability would allow physicians to tailor PCA treatment to a patient’s specific type or grade of cancer resulting in significant cost savings by minimising unnecessary or overly aggressive treatments as well as eliminating the adverse effects that invariably accompany unnecessary treatments.Health Discovery has an ongoing collaboration with investigators at Stanford University who have generated both gene- and protein-expression data from cancerous and normal prostate tissues.
